The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's Syndrome

British Journal of Obstetrics and Gynaecology

Volumn 108, Issue 10, 2001, Pages 1047-1052

  Michailidis, G D ^a   Spencer, K ^b   Economides, D L ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT;

ADOLESCENT; ADULT; AGE; ARTICLE; BIOCHEMISTRY; CHILDBIRTH; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNITY WARD; PREDICTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; MATERNAL AGE; MIDDLE AGED; NECK; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, PRENATAL;

EID: 0034793122     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-5456(01)00241-8     Document Type: Article

References (28)

1. Maternal age-standardisation of prevalence of Down's Syndrome
2. Toward the optimal protocol for Down syndrome screening
3. Second trimester prenatal screening for Down's Syndrome using alpha- fetoprotein and free beta hCG: A seven year review
4. Maternal serum free beta hCG screening: Results of studies including 480 cases of Down's Syndrome
5. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
6. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A
7. Integrated screening for Down's Syndrome on the basis of tests performed during the first and second trimesters
8. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population
9. Assessment of fetal anatomy at 12 to 13 weeks of gestation by transabdominal and transvaginal sonography
10. The effect of fetal neck position on nuchal translucency measurement
11. Screening for Down's Syndrome using serum alpha fetoprotein: A retrospective study indicating caution
12. Free beta human choriogonadotropin in Down's Syndrome screening: A multicentre study of its role compared with other biochemical markers
13. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's Syndrome
14. Calculating correct Down's Syndrome risks
15. Correct estimation of parameters for ultrasound nuchal translucency screening
16. Increased nuchal translucency as a marker for fetal chromosomal defects
17. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population
18. Screening of maternal serum for fetal Down's Syndrome in the first trimester
19. Antenatal screening for Down's Syndrome: Where are we and where next?
20. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's Syndrome
21. The significance of choroid plexus cysts, echogenic heart foci and renal pyelectasis in the first trimester
22. The role of ultrasonographic markers for trisomy 21 in women with positive serum biochemistry
23. The role of ultrasonographic markers for trisomy 21 in women with negative serum biochemistry
24. Six year survey of screening for Down's Syndrome by maternal age and mid-trimester ultrasound scans
25. The lambda sign at 10-14 weeks of gestation as a predictor of chorionicity in twin pregnancies
26. First trimester sonographic detection of chromosomal abnormalities in an unselected population
27. One stop clinic for assessment of risk for fetal anomalies: A report of the first year of prospective screening for chromosomal anomalies in the first trimester